Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | ISCT 2021 highlights: BMT, gene therapy & lymphodepletion

Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, offers some highlights in stem cell engineering and bone marrow transplantation (BMT) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021. Dr Boelens describes a plenary session exploring the latest data and considerations in gene therapy and BMT for the treatment of hemoglobinopathies, as well as a international debate on the use of different transplant platforms. In addition, he discusses a plenary focused on lymphodepletion, its impact on the efficacy and toxicity of chimeric antigen receptor (CAR) T-cell therapy and data on the pharmacokinetics of these agents. This interview took place during the ISCT Annual Meeting 2021.

Disclosures

Jaap Boelens has served as a consultant for: BlueRock, Omeros, Sanofi, Advanced Clinical, AvroBio, Race Oncology and Medexus.